Earnings Call Transcripts

Access detailed transcripts and key takeaways from company earnings calls

All Earnings Calls

TBLA May 6, 2026

Taboola Q1 2026 Earnings Call - Raised Full-Year Guidance on Realize Momentum and Share Buybacks

Taboola delivered a strong start to 2026, with Q1 results beating the high end of guidance across all metrics, driven by continued adoption of its AI-powered Realize platform. Revenue grew 9% year-ove...

  • Q1 2026 revenue grew 9% year-over-year to $466.4 million, beating the high end of guidance.
  • Ex-TAC gross profit increased 11% year-over-year to $168.1 million, reflecting strong advertiser spend and Realize adoption.
  • Management raised full-year guidance, now expecting revenue of $2.00 billion to $2.06 billion and ex-TAC gross profit of $760 million to $781 million.
  • +10 more takeaways
EYPT May 6, 2026

EyePoint Pharmaceuticals Q1 2026 Earnings Call - DURAVYU Phase III Momentum Accelerates as Cash Runway Extends to Late 2027

EyePoint Pharmaceuticals reported a sharp revenue drop to $0.7 million in Q1 2026 as deferred licensing fees from the YUTIQ deal concluded, while operating expenses rose to $88 million to fund two Pha...

  • Revenue fell to $0.7 million in Q1 2026 from $24.5 million in Q1 2025, driven by the conclusion of deferred revenue recognition from the 2023 YUTIQ licensing agreement.
  • Operating expenses increased to $88 million from $73 million in the prior year period, primarily due to ongoing Phase III trials for DURAVYU and scaling of the Northbridge commercial manufacturing facility.
  • The company reported a net loss of $85 million, or $0.99 per share, compared to a net loss of $45 million, or $0.65 per share, in the prior year period.
  • +9 more takeaways
TFPM May 6, 2026

Triple Flag Precious Metals Q1 2026 Earnings Call - Record Start Driven by High-Margin Cash Flow and Accretive U.S. Copper Royalty

Triple Flag Precious Metals delivered a historic first quarter, shattering records across every key metric with 30,000+ GEOs, $129 million in adjusted EBITDA, and a 67% surge in operating cash flow pe...

  • Q1 2026 marks the strongest quarter in company history across every key metric, including over 30,000 GEOs, $129 million in adjusted EBITDA, and $0.55 in operating cash flow per share.
  • Operating cash flow per share surged 67% year-over-year, driven by high-margin exposure to rising gold and silver prices and the model functioning as intended.
  • The company unlocked the high-grade E44 gold deposit at Northparkes, securing guaranteed minimum deliveries over seven years starting in 2030, aligning with Evolution Mining's block cave and mill expansion plans.
  • +8 more takeaways
CVS May 6, 2026

CVS Health Q1 2026 Earnings Call - EPS Guidance Raised to $7.30-$7.50 as Aetna Margins Recover

CVS Health delivered a strong first quarter, driving a 14% year-over-year increase in adjusted earnings per share to $2.57. The company responded to this momentum by raising its full-year 2026 adjuste...

  • Adjusted EPS of $2.57 beat expectations, driving a full-year 2026 guidance raise to $7.30-$7.50, up from $7.00-$7.20.
  • Revenue surged over 6% year-over-year to $100 billion, with adjusted operating income increasing 12% to $5.2 billion.
  • Aetna’s medical benefit ratio improved to 84.6% in Q1, reflecting strong medical cost management and favorable prior year development.
  • +12 more takeaways
LIVN May 6, 2026

LivaNova PLC Q1 2026 Earnings Call - OSA FDA Approval and Epilepsy Reimbursement Tailwind Drive Upgraded Guidance

LivaNova delivered a strong first quarter, posting 11% constant currency revenue growth driven by durable performance in its cardiopulmonary and epilepsy segments. The company raised its full-year 202...

  • LivaNova reported Q1 2026 revenue of $362 million, an 11% increase on a constant currency basis, driven by strength across all regions and both core businesses.
  • Full-year 2026 revenue growth guidance was raised to 7%-8%, up from 6%-7%, aligning with the high end of the company’s 2025-2028 growth framework.
  • Cardiopulmonary revenue grew 14% in Q1, with heart-lung machine revenue in the high teens and consumables in the mid-teens, supported by Essenz placements and market share gains.
  • +7 more takeaways
NC May 6, 2026

NACCO Industries Q1 2026 Earnings Call - Strong Profit Growth Driven by Utility Coal and New Infrastructure Contracts

NACCO Industries delivered a robust start to 2026, with first-quarter operating profit jumping 43% year-over-year and adjusted EBITDA rising 28%. The gains were anchored by improved efficiency at Miss...

  • First-quarter operating profit surged 43% year-over-year and 45% sequentially, with adjusted EBITDA up 28% year-over-year to $16.4 million.
  • Mississippi Lignite Mining Company drove utility coal segment strength, with operating profit doubling year-over-year to $7.4 million as cost per ton fell and reclamation activities offset reduced deliveries during a power plant outage.
  • Contract mining revenues jumped 32% year-over-year, fueled by the commencement of a multi-year dragline services contract for the U.S. Army Corps of Engineers in Florida and increased limestone deliveries.
  • +7 more takeaways
LAW May 6, 2026

CS Disco Q1 2026 Earnings Call - AI Platform Launch Drives Revenue Beat and Margin Expansion

CS Disco delivered a strong Q1 2026, beating revenue and adjusted EBITDA guidance as the launch of the all-in-one DISCO Platform and deepening AI adoption accelerated growth. Total revenue rose 14% ye...

  • Total revenue grew 14% year-over-year to $41.9 million, beating the high end of guidance.
  • Software revenue increased 12% to $34.7 million, marking the fourth consecutive quarter of accelerating growth.
  • Adjusted EBITDA improved 600 basis points to a negative $3.5 million, outperforming the high end of guidance.
  • +7 more takeaways
GOLF May 6, 2026

Acushnet Company Q1 2026 Earnings Call - Accelerated GTS Driver Launch and Tariff Uncertainty Offset by Strong Equipment Growth

Acushnet delivered a solid first quarter, with net sales rising 5% constant currency to $753 million and adjusted EBITDA up 4% to $145 million. The results were driven by strong momentum in Titleist g...

  • Worldwide net sales increased 5% on a constant currency basis to $753 million in Q1 2026.
  • Adjusted EBITDA rose 4% year-over-year to $145 million, up $6 million from Q1 2025.
  • Titleist golf equipment sales grew 7%, supported by strong demand for balls and clubs.
  • +7 more takeaways
RPRX May 6, 2026

Royalty Pharma Q1 2026 Earnings Call - Double-Digit Growth and R&D Co-Funding Surge

Royalty Pharma delivered a robust first quarter, growing portfolio receipts by 10% and recurring royalty receipts by 13%, driven by a diversified portfolio and strong clinical catalysts. Management ra...

  • Royalty Pharma reported 10% growth in portfolio receipts and 13% growth in recurring royalty receipts for Q1 2026, demonstrating the resilience of its diversified portfolio.
  • Management raised full-year 2026 guidance for portfolio receipts to $3.325 billion–$3.45 billion, up from the previous range of $3.275 billion–$3.425 billion.
  • The company announced $1.25 billion in new transactions, including a $250 million upfront investment for a royalty on Ziihera, a HER2-targeted cancer therapy with blockbuster potential in gastric cancer.
  • +9 more takeaways
SEDG May 6, 2026

SolarEdge Q1 2026 Earnings Call - Transitioning to Offensive Growth with Near-Break-Even Results and Strategic Shifts

SolarEdge delivered a pivotal Q1 2026 report that underscores a decisive shift from defensive cost-cutting to offensive growth, marked by 46% year-over-year revenue expansion and a clear path to near-...

  • Q1 revenue surged 46% year-over-year to $310 million, marking the fifth consecutive quarter of growth without significant revenue pull-forward.
  • Management guided for Q2 revenue between $325-$355 million, with a midpoint EBIT loss of approximately $3.5 million, signaling a near-break-even milestone.
  • Non-GAAP gross margin expanded slightly to 23.5%, driven by a favorable product mix and lower seasonal warranty costs, while operating expenses came in well below guidance.
  • +7 more takeaways